Quest Diagnostics Q3 2024 Earnings Call: A Deeper Look
Introduction
On October 22, 2023, Quest Diagnostics Incorporated (NYSE:DGX) held its Q3 2024 earnings conference call. The call was led by Jim Davis, President and Chief Executive Officer, and Sam Samad, Executive Vice President and Chief Financial Officer.
Key Takeaways
Before diving into the details, let’s highlight the main points from the call:
- Quest Diagnostics reported its Q3 2024 earnings, providing insights into the company’s performance.
- The call included a presentation and a question-and-answer session with various analysts.
- The company’s executives discussed non-GAAP measures and provided a reconciliation to comparable GAAP measures.
The Call
Shawn Bevec, Vice President of Investor Relations, introduced the call, emphasizing that the entire contents, including the presentation and Q\&A session, are copyrighted property of Quest Diagnostics.
Executive Insights
Jim Davis and Sam Samad led the discussion, covering key aspects of the company’s performance. They also addressed questions from analysts, including Ann Hynes from Mizuho Securities, Michael Cherny from Leerink Partners, and Patrick Donnelly from Citi, among others.
Forward-Looking Statements and Non-GAAP Measures
During the call, the executives made forward-looking statements and discussed non-GAAP measures. They provided a reconciliation of these measures to comparable GAAP measures in the tables accompanying the earnings press release.
Risks and Uncertainties
As with any forward-looking statements, actual results may differ materially from those projected. Quest Diagnostics’ future results are subject to risks and uncertainties, which are described in the company’s most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q.
Analyst Participation
The call included participation from various analysts, representing firms such as Deutsche Bank, Jefferies, Piper Sandler, and Nephron Research, among others.
Leave a Reply